Beijing Tiantan Hospital Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2016
NCT02934256
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Li Peng | Yang Zhang

Active Ingredients

Drugs in Phase 2 Trials (1)

icotinib (1 trial)

Drugs in Phase 1 Trials (1)

histone h3.3-k27m neoantigen vaccine therapy (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neurilemmoma (Phase 2)

Neurofibroma (Phase 2)

Neurofibromatoses (Phase 2)

Neurofibromatosis 1 (Phase 2)

Neurofibromatosis 2 (Phase 2)

Neuroma, Acoustic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2